ATTR Amyloidosis in Elderly Patients With Aortic Stenosis

Amyloidosis Cardiac Clinical Trial

Official title: ATTR Amyloidosis in Elderly Patients With Aortic Stenosis

Status Active, not recruiting

Clinical Trial Summary

Severe aortic stenosis is defined with a mean transvalvular pressure gradient (MTPG) > 40mmHg and a calculated aortic valve area of < 1cm2. However, a considerable proportion of patients do have a MTPG < 40mmHg due to a reduced stroke volume (stroke volume indexed to body surface area ≤ 35ml/m2) despite a normal left ventricular ejection fraction (LVEF > 50%). This entity is termed paradoxical low flow low gradient aortic stenosis (PLFLG AS) and is associated with a worse prognosis.

ATTR amyloidosis is a disease of the elderly and might coexist in patients with severe aortic stenosis. Case reports and small observational studies suggest that senile ATTR amyloidosis could be frequent but underdiagnosed in patients with aortic stenosis. There is significant overlap between PLFLG AS and cardiac amyloidosis with regard to symptoms, increasing prevalence with age, concentric hypertrophy, impaired diastolic filling of the left ventricle (LV), as well as longitudinal LV dysfunction despite preserved ejection fraction - all features, which lead to a reduction in stroke volume, the underlying mechanism of the low flow condition as observed in PLFLG AS patients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Amyloidosis
• Amyloidosis Cardiac
• Aortic Stenosis Symptomatic
• Aortic Valve Stenosis
• Constriction, Pathologic

• NCT number: NCT04061213
• Study type: Observational [Patient Registry]
• Source: University Hospital Inselspital, Berne
• Status: Active, not recruiting
• Start date: August 26, 2019
• Completion date: December 2022